Here are the 10-K annual reports from Pacira BioSciences, Inc. (PCRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCRX filings page.
Pacira BioSciences provides a detailed update on its non-opioid pain franchise and growth strategy for the year ended December 31, 2025. EXPAREL remains the core product, with net product sales of $575.1 million, representing 79% of total revenue. ZILRETTA generated net product sales of $116.6 million and iovera° $24.2 million.
The company highlights its “5x30” plan to 2030, targeting double-digit product revenue growth, gross margin improvement and at least five clinical programs and five partnerships. It reports reaching 2.5 million patients in 2025 and adding strategic partnerships for EXPAREL and ZILRETTA.
Pacira expands on its pipeline, led by gene therapy candidate PCRX-201 for knee osteoarthritis, which has Phase 1 data and is in Phase 2 development with RMAT and ATMP designations. It also acquired the remaining stake in GQ Bio Therapeutics and licensed PCRX-2002 from AmacaThera.
The filing describes extensive clinical data supporting EXPAREL, ZILRETTA and iovera°, the IGOR real‑world outcomes registry, manufacturing capacity with Thermo Fisher and internal facilities, and key commercial agreements. It also notes a Paragraph IV settlement that allows limited generic EXPAREL entry starting in early 2030 and a favorable royalty dispute judgment requiring RDF to repay $23.1 million plus $5.2 million interest.